Outcomes in COVID-19 avdoralimab studies

0 0.5 1 1.5+ All studies -68% 1 207 Improvement, Studies, Patients Relative Risk Mortality -68% 1 207 RCTs -68% 1 207 Late -68% 1 207 Avdoralimab for COVID-19 c19early.org November 2025 Favorsavdoralimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] death 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Effect extraction pre-specified(most serious outcome) Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] death 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Effect extraction pre-specified(most serious outcome) Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] death 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Effect extraction pre-specified(most serious outcome) Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] death 20/103 12/104 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk All studies -68% 1.68 [0.87-3.26] 20/103 12/104 68% higher risk 1 avdoralimab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Effect extraction pre-specified(most serious outcome) Favors avdoralimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FORCE Carvelli (DB RCT) -68% 1.68 [0.87-3.26] death 20/103 12/104 Improvement, RR [CI] Treatment Control FORCE Carvelli (DB RCT) -96% 1.96 [0.52-7.40] death 6/50 3/49 FORCE Carvelli (DB RCT) -108% 2.08 [0.42-10.3] death 4/24 2/25 FORCE Carvelli (DB RCT) -48% 1.48 [0.65-3.36] death 10/29 7/30 Avdoralimab COVID-19 outcomes c19early.org November 2025 Favors avdoralimab Favors control